AstraZeneca Covid-19 vaccine not advised for above 65 years! Is Germany valid to zero this out?

Last updated on February 6th, 2021 at 08:41 am

Germany has just issued an advisory against giving the Oxford-AstraZeneca vaccine to people over 65 years of age. The reasons for this specific age bracket aren’t arbitrary but are backed by reason. 

The foremost reason of Germany issuing the recommendation is the lack of evidence. German disease control agency, Robert Koch Institute’s vaccination standing committee has underlined insufficient data available to govern efficacy of vaccine on people over 65 years of age. The researchers mentioned in the study published in The Lancet that due to lack of Covid-19 cases at time in older adults, vaccine efficacy can’t be established. 

The team had written, “Vaccine efficacy in older age groups could not be assessed but will be determined, if sufficient data is available, in a future analysis after more cases have accrued.” 

Oxford’s Prof Andy Pollard said that lack of data is reasonable as older adults were recruited later in trial as number of cases were very less due to their cautiousness in pandemic. AstraZeneca said that older adults were included in trial later. 

So, what does it mean for efficacy of vaccine in older adults? 

Dr. Simon Clarke, associate professor in Cellular Microbiology at the University of Reading said, “It’s important to stress that this is not evidence that the vaccine does not work, merely that the evidence does not currently exist to satisfy the authorities in Germany.” 

Some encouraging data is shared by Oxford – immune responses in older people are similar as shown in younger adults. Prof Pollard said, “We have seen a good immune response in healthy older adults in the phase 2 study and the MHRA reviewed further data on immune response in the phase 3 trial.” 

Germany’s issuance of an age limit for the vaccine is confusing for experts. Prof Danny Altmann of Imperial College London said, “When I look at the AZ phase 3 data for the over 70-group, I see a good response, similar to the other age groups.” 

On Monday, Handelsblatt, a German newspaper, claimed that AstraZeneca is showing as low as 8% efficiency in older adults as said by an unnamed source. The claims have been dismissed by AstraZeneca. German authorities have come to figure of 6.3% efficiency among older people, something rejected y experts as it is based on only 2 infections. 

Many experts also say that ongoing tussle between EU and AstraZeneca may have influenced Germany’s decision. 

Related Posts

For concerned older people as of efficiency and safety of the vaccine, experts say that the AstraZeneca vaccine is both safe and efficient for all people, including older adults. 

Prof Stephen Evans, Pharmacoepidemiology professor at London School of Hygiene and Tropical Medicine said, “There is no reason at all for anyone in the UK or elsewhere to think that this Oxford/ AstraZeneca vaccine is ineffective at any age. Its ability to be delivered to people in GP surgeries and care homes makes it a vital component in the attempts to reduce hospitalization and deaths, especially in the elderly.” 

Neha M

Recent Posts

Austria’s Infrastructure Ambition: How Austria’s Infrastructure Investment Is Redefining Europe’s Future

Austria is becoming an exception story in Europe that is succeeding by investing in long-term investment in infrastructure. Austria infrastructure… Read More

December 13, 2025

Sudan’s Crisis in Focus: What BBC Investigations and Al-Hurra Reports Reveal

The crisis in Sudan has quickly turned into one of the most threatening crises in the area that involves humanitarian… Read More

December 13, 2025

Key Middle East Rail Project Updates You Should Know

This article on modern mobility, sustainable transport and across-border connectivity describes how the Key Middle East rail project is being… Read More

December 12, 2025

Planning To Travel To Europe In 2026? Here Are 7 Key Updates You Need To Be Aware Of

Planning a trip to Europe in 2026? The continent will present some of the biggest changes that will impact global… Read More

December 12, 2025

UAE Pledges $550 Million to Boost UN’s 2026 Global Humanitarian Response

The United Arab Emirates is a country that has announced a significant humanitarian initiative by promising USD 550 million to… Read More

December 11, 2025

Europe’s Path to a Unified Clinical Trials Ecosystem

Europe is also striving to create a single clinical trials ecosystem so it can enhance its standing in international medical… Read More

December 11, 2025

This website uses cookies.

Read More